Q4 2025 DiaMedica Therapeutics Inc Earnings Call Transcript
Key Points
- DiaMedica Therapeutics Inc (DMAC) reported significant progress in 2025, achieving key milestones across its pipeline.
- Positive interim results from the Phase 2 trial of DM199 in preeclampsia showed statistically significant reductions in blood pressure and uterine artery pulsatility index.
- DM199 demonstrated a favorable safety profile by not crossing the placental barrier, reducing fetal risk in preeclampsia treatment.
- The company received regulatory clearance from Health Canada to initiate a global Phase 2 clinical trial of DM199 in early onset preeclampsia.
- DiaMedica's cash position is strong, with $59.9 million in cash and investments, expected to fund operations through the end of 2027.
- Enrollment in the Part II expansion cohort for preeclampsia is slower than expected due to staffing challenges.
- The FDA requested additional reproductive toxicology studies, and the current rabbit model may not be suitable due to immune response issues.
- Research and development expenses increased significantly, driven by the continuation and expansion of clinical trials.
- General and administrative expenses rose due to increased personnel costs and investor relations expenses.
- The company faces challenges in enrolling stroke patients due to initial triage in community hospitals, potentially impacting real-world access.
Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics full-year 2025 earnings conference call. An audio recording of this webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.
Before the company proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause the actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results appear in the section entitled Cautionary Statement Note regarding Forward-Looking Statements in the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K.
DiaMedica's SEC filings are available at www.sec.gov and on its website.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
